Market Research Report
Competitor Analysis: Cancer Antibodies in Early Clinical Development
|Published by||La Merie Publishing||Product code||166719|
|Published||Content info||183 Pages
|Competitor Analysis: Cancer Antibodies in Early Clinical Development|
|Published: February 1, 2011||Content info: 183 Pages||
This publication has been discontinued on July 3, 2017.
The present Competitive Intelligence Report about Cancer Antibodies in Early Clinical Development provides a competitor evaluation in the field of antibody therapeutics being developed for treatment of solid and hematologic malignancies as of February 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Marketed therapeutic antibodies for treatment of cancer achieved combined sales of over US$ 18 bln in the year 2009. Among them are the blockbuster antibodies Avastin, Rituxan/MabThera and Herceptin. The development pipeline of novel cancer antibodies in early clinical phases is full, not only of antibodies against the validated targets CD20, VEGF and Her2, but also of many new and unique antibodies directed against novel targets which will have to show its clinical validity. The technology of antibody-drug conjugates is gaining popularity as evidenced by an ever growing pipeline.
The report includes a compilation of currently active projects in early clinical research and development of antibody therapeutic for treatment of cancer. In addition, the report lists company-specific R&D pipelines of anti-cancer antibodies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.